Not saying that they should not get their results published, but not in lieu of releasing the date now. Peer review publications take months or longer. Give us the results now, so others can see we have a complete vaccine ready to got to trials. Would you not prefer the price movements of the 3 major vaccine candidates that did not wait for peer review publications, or the price movement of GNBT while we wait in silence of the results?

Sure would be nice if GNBT were to release the blood test results of the 33 peptide vaccine candidates. Rich Purcell said in Dr Yo interview, that they will release them in a peer paper. Why? That is what you do when you have long term trials and you want your data peer reviewed. However time is of the essence here. Give us the results that Rich Purcell said were better than expected.

You're welcome. I considered buying into these Preferreds, when they were first announced, however I won't. The warrants to buy GNBT at $15 (we are at $0.22) and at only a 1 for 10 ration, is not enough enticement. The 13% dividend is meaningless, since they are taking 39% of the money I would give them, on a after tax basis, creating a sinking fund to pay me back as a dividend (which is now taxable to me) does not make sense. Just not for me.

GENEREX BIOTECHNOLOGY CORPORATION
1,000,000 Shares of Series A Cumulative Redeemable Perpetual Preferred Stock
Warrants to purchase up to 100,000 Shares of Common Stock


Generex Biotechnology Corporation is offering 1,000,000 shares of its Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) and warrants (“Warrants”) to purchase up to an aggregate of 100,000 shares of the Company’s common stock, par value $0.001 (“Common Stock”). For every ten shares of Series A Preferred Stock purchased, we will issue to such purchaser one Warrant to purchase one share of Common Stock. The Warrants will have an initial per share exercise price of $15.00. The warrants will be exercisable immediately and will expire two years from the date of issuance.



Dividends on the Series A Preferred Stock offered hereby are cumulative from the first day of the calendar month in which they are issued and will be payable on the fifteenth day of each calendar month, when, as and if declared by our board of directors. Dividends will be payable out of amounts legally available therefor at a rate equal to 13% per annum per $33.00 of stated liquidation preference per share, or $33.00 per share of Series A Preferred Stock per year.



To provide for the first three years of dividend payments on Series A Prefereed Stock we will create a sinking fund reserve into which we will deposit 39.00% of the gross proceeds of this offering. We will not have access to any amounts in the sinking fund reserve other than to pay monthly dividends on the Series A Preferred Stock.



Commencing on

Sorry neogn8, that is not entirely correct. Any investor that buys the preferred, then GNBT is putting 39% of the funds into a sinking fund to pay a 13% dividend to that investor over the next 3 years. So basically 3 years of dividends is guaranteed. However that does not mean the common shareholders are getting anything from that. In fact, the common is only benefitting by GNBT getting 61% of the proceeds to their cash balance to use to fund all the other ongoing products.

desert, investors will have the opportunity to buy into the preferreds GNBTP. They have to be approved by the SEC first with an EFFECT on the S1. It has nothing to do with the common shares of GNBT though. I'm sure more info will come after approval.

Unfortunately that is not the case. However the preferreds will bring in the funds to get rid of going concerns and then they can list NGIO or uplist GNBT.

myjo I don't follow you there. Why would existing shareholders be screwed? They are offering preferred shares to raise funds without diluting existing shareholders.

Thanks. Do you have a link to that so I can review? Appreciate it. I have the 8/21 $5 call options so I only have another 7 days.

Any news? CEMI popped up from $5.23 to $6.21 at 1:05PM EST on 2.6M shares.

Very simple answer, cut and paste from Monday’s PR about the GNBT conf call on Wednesday 8/26. At the bottom of that PR, they say the exact same line about looking forward to speaking with shareholders on August 26th. So it is a cut and paste error.

The real question is whether the call for Both Wednesday and Thursday at 9:30AM as stated in the title, or 9AM as stated in the first paragraph of EACH PR.

Bottom line, sloppy PR writing, as usual.

Are you sure? I've heard of several people that have reached out to the company and no one has responded.

I have confirmed with TD Ameritrade that they DO NOT LEND OUT OTC STOCKS FOR SHORTING. So you can still have a position in your margin acct. obviously CYDY can not be purchased on margin either at TDA.

Still have all my NGIO shares at TDA (still say Antigen Express though there).

Which S1? If you mean the one GNBT filed to the SEC like 4 months ago, not too quick lol. We need them to approve that so GNBT can get moving on all their initiatives that are bottlenecked right now.

If you mean the one they “will” file for NGIO, well we need to know the comments from the SEC from the filed amended form 10 from 30 days ago has been satisfied.

Meanwhile, we will have to live vicariously thru the other stock we both own...wink wink.

Yes, once on nasdaq, Robinhood traders will flock to CYDY. I can’t wait. Also for option trading. I trade a lot in options.

Actually, dropping the news tonight gets it picked up by many more news organizations. That gets news going overnight rather than the normal 6AM release. This was excellent and already picked up by Dow newswire so that is great.

That is correct.

Robinhood does not let otc trading.

Excellent point docj.

Probably not. They have to have all
Sec comments satisfied first. That could be tomorrow or 30 days from now. Then file the S1, which can take up to 60’days to review. So most likely won’t be until sept-nov.

Looks like it was trying to move again like yesterday, but stalled so far. Even though it’s down, it is above its 50 period EMA.

Mine still say Antigen express at TDA.

https://chembiodiagnosticsinc.gcs-web.com/news-releases/news-release-details/chembio-announces-plans-seek-eua-approval-fda-revised-dpp-covid


https://chembiodiagnosticsinc.gcs-web.com/news-releases/news-release-details/chembio-diagnostics-awarded-barda-contract-development-dpp-covid

Thanks docj, I will. I have been reading along and love the prospects for cydy. My only concern is if the stock gets ahead of itself, hence why I trade it right now. As deals get done and revenue comes in, I may decided to change to a longer term investment instead. Meanwhile, we can all make money. You have your long term capital gains and I have my short term capital gains, and we are both making money. Thx

Is this part of tonight’s announcements? New government contract?

https://beta.sam.gov/awards/90975785%2BAWARD

Thank you. And just because I sell at $10-15 or $20, doesn’t mean I won’t buy back in on a dip, or even higher if it still shows strength.

And totally understand being committed to a stock. Docj, hoops and I have been in GNBT for 10-17 years ( me being the 17). I have 35% of my portfolio in GNBT, so that is a very large position. They got a new CEO 3 1/2 years ago that is on the cusp of a turnaround for the textbooks. And I would take $10-15 on them right now too. However they will go much higher if their spin out of NGIO (not public trading yet) gets listed on nasdaq. FYI, they only have 80M shares outstanding compared to CYDY 520M.

Good luck.

Not me. I learned of CYDY from docj and hoops on another board. They had been suggesting I look at CYDY from the $0.30-0.50 level. Of course I did not listen. I’m in now and truly want the stock to go up.

If I was in CYDY at the time, I would have sold on the several days of upwards movement. Fact is I have been in and out of CYDY several times already. I sold at $7.65 on Monday 6/29 and missed out on the late day rally to $8.85. Then Tuesday’s gap open and run to $10. However I did buy back in on the pullback at $8.50 then again at $7.51 then again at $6.65. I sold the $6.65 on the bounce to $7.39, and bought more back on the dip at $5.27. So I have a decent position and would love $100, but will take $10-15 this week if it hits. I sell on momentum and sell on momentum. I may hold some for a longer term position.

About a month ago, there was an article about his struggle. I posted on his, and his wife’s, Instagram and twitter feeds about contacting Nader about leronlimab. Sadly they must not have seen my posts, or been able to act on them.

Again, don’t get me wrong, I am looking for CYDY to go up, but triple digits is not reasonable. Just keeping it real. I say $10-20 is it for now. OTC don’t have the short interest of listed stocks to get a short squeeze.

Thx for the reply. I agree maybe in the future, years from now with multiple uses APPROVED for Leronlimab, then you could get to triple digits. My point was that I don’t believe Nader should be discussing triple digit or 4 digit price targets. That is not for a CEO to me promoting without an approved product or sales. That is the kind of talk that gets lawsuits in the future. Let’s say Leron gets approved for Covid and HIV this year, how many vials can be manufactured and sold? With a significant share count of 520M already, I would think $10-15 maybe $20 is possible. However triple digit and quad digit are not a reality and investors should know that. Docj knows me well. I am a long time investor with him in GNBT. However I trade ALOT now in stocks and options and doing quite well. So use reasonable expectations for CYDY stock price.
That being said, I am long CYDY and would be happy to get $10-15.
Good luck.

While I would like to see $100+, that would make the market cap $52B+. That is not possible right now without tens of billions in revenue.

Yes, the green line is the # of Robinhood users that own the stock that day.

No there is no way to show they are truly robinhood traders, however look at the link. You will see the green line of the # of robinhood traders that are in POLA at the end of the day each day. They increase significantly. They same thing happened on VXRT. Look at what has happened to their stock and check out the significant robinhood traders in it. They make runs. I don't have a link, however I have heard they have a message board somewhere that they coordinate what stock to go into next. Just like Hertz, Chesapeake Oil, Whiting Oil, etc.
https://www.robintrack.net/symbol/VXRT

It is the daytrading of Robinhood traders. Expect this to continue for several days. I expect another spike up.
https://www.robintrack.net/symbol/POLA

I rec'd 2 different links to the presentation. The first one when I registered about 45 minutes ago, and then another link about 20 minutes ago. The 2nd link is working right now and I am listening to the presentation. The first link from registration is sitting as waiting for presentor.

CORONAVIRUSPublished 1 hour ago
Experimental coronavirus treatment leronlimab has delivered 'impressive' early results, developer says
By James Rogers | Fox News
Facebook
Twitter
Flipboard
Comments
Print
Email
Harvard study finds US needs to triple current testing for coronavirusVideo
Harvard study finds US needs to triple current testing for coronavirus
Reaction and analysis from Harvard Global Health Institute's Dr. Ashish Jha on ‘America’s News HQ.’

Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.


The experimental coronavirus treatment leronlimab has reduced the plasma viral load and restored the immune system of COVID-19 patients, according to data from a small group of patients.


“The results are impressive,” said Nader Pourhassan, the CEO of biotech firm CytoDyn during a conference call Monday.

Leronlimab is a viral-entry inhibitor that has targeted HIV and breast cancer. The drug also has been attracting attention as a potential coronavirus treatment, particularly to quell the so-called “cytokine storm,” when COVID-19 has caused the immune system to go awry.

“Leronlimab decreases plasma viral load,” said Dr. Bruce Patterson, the CEO of diagnostic specialist IncellDX during the conference call, noting that leronlimab also restored immune cells.

Patterson said his lab performed a blood-sample analysis of the first 10 COVID-19 patients enrolled in Emergency Investigational New Drug treatments at Montefiore Medical Center.

“That is remarkable for one drug to restore the immune system and decrease the viral burden in these patients,” Patterson added. “That is what gives us great hope and great excitement about leronlimab going forward in these trials.”


CytoDyn has been enrolling patients in two clinical trials for COVID-19: a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 patients in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 patients in several hospitals throughout the country, company executives said in a statement.

Leronlimab has been one of multiple drugs in the spotlight as the world scrambled to contain the coronavirus pandemic. Many experts, however, have warned that people should not take drugs unless a doctor prescribes them.

CytoDyn recently announced leronlimab had shown a “very promising” response in COVID-19 patients with mild-to-moderate symptoms.

“Vaccine by Generex

Generex has announced that it is developing a COVID-19 vaccine following a contract from a Chinese consortium comprising of China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development.

The company will utilise its Ii-Key immune system activation technology to produce a COVID-19 peptide for human clinical trials.

Generex will receive an upfront payment of $1m to commence the groundwork for the vaccine development and $5m licensing fee for its Ii-Key technology. It is also eligible to receive a 20% royalty on every dose of vaccine produced under the contract.”

https://www.clinicaltrialsarena.com/analysis/...cov-drugs/

Amen bwolf. More likely there 200K shares at 0.45 conversion, would cost them $90K right now. Waiting for a buyout, if it comes, they know they can put out the money and get a quickish return on the conversion cost.